Ask AI
FLT3i AEs in AML

CME

Optimizing FLT3 Inhibitors: Strategies for Early Detection and Management of Adverse Events

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 29, 2025

Expiration: February 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following AEs is commonly associated with differentiation syndrome during FLT3 inhibitor therapy in AML?

2.

A 65-year-old man with newly diagnosed FLT3-mutated AML is scheduled to receive induction chemotherapy with cytarabine and an anthracycline, and the team plans to add quizartinib. His baseline QTcF is 430 ms, and he has no cardiovascular comorbidities. Supportive care will include antifungal prophylaxis with posaconazole. Which of the following is the most appropriate next step in managing this patient?